HealthActCHQ's portfolio of surveys represents scientific work that spans more than two decades. Our surveys are used throughout the world in clinical trials, registries, and benchmarking/best practice reporting programs. All HACHQ surveys are rigorously developed to include feedback from children and adults - varying in diagnosis and its related subtypes, disease/condition severity, treatment status and time of onset/diagnosis - as well as feedback from clinical experts.

HealthActCHQ has conducted the translation of more than 126 versions of the CHQ in over 61 languages. We are the developers and exclusive licensor for the AIM-A, an industry-leading ADHD survey used internationally and now available in 12 languages and the AIM-C, the only published ADHD quality of life survey for children and their families.

Our surveys have a long-lineage including publication in peer-reviewed journals.

Our surveys meet or exceed 2006 FDA guidelines on patient-reported outcomes and respond to the following U.S. and European Union legislative directives:

• U.S. FDA Center for Drug Evaluation and Research, Best Pharmaceuticals for Children Act, 4 January, 2002 (Public Law No. 107-109)
• U.S. FDA Center for Drug Evaluation and Research, Pediatric Research Equity Act of 2003 (Public Law No. 108-155)
• The Paediatric Regulation (Regulation (EC) No 1901/2006) of the European Parliament, 26 January 2007.

All HealthActCHQ surveys require registration and licensure for each specific project as well as payment for licensing fees.

You can register without any obligation to purchase. Ongoing management, support, and scientific development for the CHQ and all other HACHQ surveys - short-forms, translations, utility-based scoring - are funded exclusively by licensing fees.

| TOP |